Regeneron Pharmaceuticals, Inc. has filed its monoclonal antibody therapy REGN-COV2 with the US Food and Drug Administration for emergency use authorization, announcing the submission just hours after President Trump praised it as a "cure" for COVID-19.
Discussions with the US regulator about a potential EUA had already begun after the company announced promising results two weeks...







